Evidence map›Paper›PMID 40340717›Full record

ArticleJournal of translational medicine2025

Reproducibility of genetic risk factors identified for long COVID using combinatorial analysis across US and UK patient cohorts with diverse ancestries.

J Sardell, M Pearson, K Chocian, S Das, K Taylor, M Strivens, R Gupta, A Rochlin, S Gardner

Abstract read
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Neuroimmune pathophysiology of long COVID.Psychiatry and clinical neurosciences · 2025
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

J SardellPrecisionLife Ltd., Unit 8b Bankside, Hanborough Business Park, Long Hanborough, OX29 8LJ, UK.
M PearsonPrecisionLife Ltd., Unit 8b Bankside, Hanborough Business Park, Long Hanborough, OX29 8LJ, UK.
K ChocianPrecisionLife Ltd., Unit 8b Bankside, Hanborough Business Park, Long Hanborough, OX29 8LJ, UK.
S DasPrecisionLife Ltd., Unit 8b Bankside, Hanborough Business Park, Long Hanborough, OX29 8LJ, UK.
K TaylorPrecisionLife Ltd., Unit 8b Bankside, Hanborough Business Park, Long Hanborough, OX29 8LJ, UK.
M StrivensPrecisionLife Ltd., Unit 8b Bankside, Hanborough Business Park, Long Hanborough, OX29 8LJ, UK.
R GuptaMetrodora Institute, 3535 South Market Street, West Valley City, UT, 84119, USA.
A Rochlin *Complex Disorders Alliance, 2299 Summer St. #1140, Stamford, CT, 06905, USA.
S Gardner *PrecisionLife Ltd., Unit 8b Bankside, Hanborough Business Park, Long Hanborough, OX29 8LJ, UK. steve@precisionlife.com.ORCID 0000-0002-5490-3358

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLong COVID is a major public health burden causing a diverse array of debilitating symptoms in tens of millions of patients globally. In spite of this overwhelming disease prevalence, staggering cost, severe impact on patients' lives and intense global research efforts, study of the disease has proved challenging due to its complexity. Genome-wide association studies (GWAS) have identified only four loci potentially associated with the disease, although these results did not statistically replicate between studies. A previous combinatorial analysis study identified a total of 73 genes that were highly associated with two long COVID cohorts in the predominantly (> 91%) white European ancestry Sano GOLD population, and we sought to reproduce these findings in the independent and ancestrally more diverse All of Us (AoU) population.

methodsWe assessed the reproducibility of the 5343 long COVID disease signatures from the original study in the AoU population. Because the very small population sizes provide very limited power to replicate findings, we initially tested whether we observed a statistically significant enrichment of the Sano GOLD disease signatures that are also positively correlated with long COVID in the AoU cohort after controlling for population substructure.

resultsFor the Sano GOLD disease signatures that have a case frequency greater than 5% in AoU, we consistently observed a significant enrichment (77-83%, p < 0.01) of signatures that are also positively associated with long COVID in the AoU cohort. These encompassed 92% of the genes identified in the original study. At least five of the disease signatures found in Sano GOLD were also shown to be individually significantly associated with increased long COVID prevalence in the AoU population. Rates of signature reproducibility are strongest among self-identified white patients, but we also observe significant enrichment of reproducing disease associations in self-identified black/African-American and Hispanic/Latino cohorts. Signatures associated with 11 out of the 13 drug repurposing candidates identified in the original Sano GOLD study were reproduced in this study.

conclusionThese results demonstrate the reproducibility of long COVID disease signal found by combinatorial analysis, broadly validating the results of the original analysis. They provide compelling evidence for a much broader array of genetic associations with long COVID than previously identified through traditional GWAS studies. This strongly supports the hypothesis that genetic factors play a critical role in determining an individual's susceptibility to long COVID following recovery from acute SARS-CoV-2 infection. It also lends weight to the drug repurposing candidates identified in the original analysis. Together these results may help to stimulate much needed new precision medicine approaches to more effectively diagnose and treat the disease. This is also the first reproduction of long COVID genetic associations across multiple populations with substantially different ancestry distributions. Given the high reproducibility rate across diverse populations, these findings may have broader clinical application and promote better health equity. We hope that this will provide confidence to explore some of these mechanisms and drug targets and help advance research into novel ways to diagnose the disease and accelerate the discovery and selection of better therapeutic options, both in the form of newly discovered drugs and/or the immediate prioritization of coordinated investigations into the efficacy of repurposed drug candidates.

Indexed as

COVID-19Genetic Predisposition to DiseaseCohort StudiesFemaleGenome-Wide Association StudyHumansMaleMiddle AgedPolymorphism, Single NucleotideReproducibility of ResultsRisk FactorsSARS-CoV-2United KingdomUnited StatesWhiteWhite PeopleCombinatorial analyticsGeneticsLong COVIDPASCPost-acute COVID-19Post COVID-19 conditionReproducibilitySARS-CoV-2

Identifiers

PMID40340717
PMCPMC12063436

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.